Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy

Translational Research

Volumn 187, Issue , 2017, Pages 32-43

  Bollino, Dominique ^a   Webb, Tonya J ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

BINDING SITE; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL HETEROGENEITY; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; ADOPTIVE IMMUNOTHERAPY; GENETICS; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 85021445472     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2017.06.003     Document Type: Review

References (120)

1. Brentjens, R.J., Curran, K.J., Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program 2012 (2012), 143–151.
2. Kim, M.G., Kim, D., Suh, S.K., Park, Z., Choi, M.J., Oh, Y.K., Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics. Arch Pharm Res 39 (2016), 437–452.
3. Savoldo, B., Ramos, C.A., Liu, E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121 (2011), 1822–1826.
4. Zhong, X.S., Matsushita, M., Plotkin, J., Riviere, I., Sadelain, M., Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18 (2010), 413–420.
5. Porter, D.L., Hwang, W.T., Frey, N.V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 7, 2015, 303ra139.
6. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
7. Brentjens, R.J., Riviere, I., Park, J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118 (2011), 4817–4828.
8. Bonifant, C.L., Jackson, H.J., Brentjens, R.J., Curran, K.J., Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics, 3, 2016, 16011.
9. Magee, M.S., Snook, A.E., Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov Med 18 (2014), 265–271.
10. Farag, S.S., Caligiuri, M.A., Human natural killer cell development and biology. Blood Rev 20 (2006), 123–137.
11. Lanier, L.L., NK cell recognition. Annu Rev Immunol 23 (2005), 225–274.
12. Cooper, M.A., Fehniger, T.A., Turner, S.C., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001), 3146–3151.
13. Raulet, D.H., Vance, R.E., Self-tolerance of natural killer cells. Nat Rev Immunol 6 (2006), 520–531.
14. Lanier, L.L., Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9 (2008), 495–502.
15. Liu, J., Xiao, Z., Ko, H.L., Shen, M., Ren, E.C., Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci U S A 111 (2014), 2662–2667.
16. Fauriat, C., Long, E.O., Ljunggren, H.G., Bryceson, Y.T., Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115 (2010), 2167–2176.
17. Raulet, D.H., Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3 (2003), 781–790.
18. Becker, P.S., Suck, G., Nowakowska, P., et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother 65 (2016), 477–484.
19. Iyengar, R., Handgretinger, R., Babarin-Dorner, A., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5 (2003), 479–484.
20. Koehl, U., Brehm, C., Huenecke, S., et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol, 3, 2013, 118.
21. Sutlu, T., Stellan, B., Gilljam, M., et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 12 (2010), 1044–1055.
22. Bachanova, V., Cooley, S., Defor, T.E., et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123 (2014), 3855–3863.
23. Vivier, E., Raulet, D.H., Moretta, A., et al. Innate or adaptive immunity? The example of natural killer cells. Science 331 (2011), 44–49.
24. Voskoboinik, I., Smyth, M.J., Trapani, J.A., Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 6 (2006), 940–952.
25. Screpanti, V., Wallin, R.P., Ljunggren, H.G., Grandien, A., A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 167 (2001), 2068–2073.
26. Bishara, A., De Santis, D., Witt, C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 (2004), 204–211.
27. Ruggeri, L., Mancusi, A., Burchielli, E., et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 40 (2008), 84–90.
28. Klingemann, H., Are natural killer cells superior CAR drivers?. Oncoimmunology, 3, 2014, e28147.
29. Kim, S., Poursine-Laurent, J., Truscott, S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005), 709–713.
30. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005), 3051–3057.
31. Imai, C., Iwamoto, S., Campana, D., Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106 (2005), 376–383.
32. Shimasaki, N., Fujisaki, H., Cho, D., et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14 (2012), 830–840.
33. Chu, Y., Hochberg, J., Yahr, A., et al. Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-Modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res 3 (2015), 333–344.
34. Altvater, B., Landmeier, S., Pscherer, S., et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 15 (2009), 4857–4866.
35. Kruschinski, A., Moosmann, A., Poschke, I., et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 105 (2008), 17481–17486.
36. Chang, Y.H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., Campana, D., A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73 (2013), 1777–1786.
37. Huenecke, S., Zimmermann, S.Y., Kloess, S., et al. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 33 (2010), 200–210.
38. Bhat, R., Watzl, C., Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies. PLoS One, 2, 2007, e326.
39. Brehm, C., Huenecke, S., Quaiser, A., et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One, 6, 2011, e27351.
40. Tonn, T., Schwabe, D., Klingemann, H.G., et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15 (2013), 1563–1570.
41. Maki, G., Klingemann, H.G., Martinson, J.A., Tam, Y.K., Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 10 (2001), 369–383.
42. Matsuo, Y., Drexler, H.G., Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leuk Res 27 (2003), 935–945.
43. Cheng, M., Zhang, J., Jiang, W., Chen, Y., Tian, Z., Natural killer cell lines in tumor immunotherapy. Front Med 6 (2012), 56–66.
44. Muller, T., Uherek, C., Maki, G., et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57 (2008), 411–423.
45. Boissel, L., Betancur, M., Lu, W., et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma 53 (2012), 958–965.
46. Boissel, L., Betancur-Boissel, M., Lu, W., et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology, 2, 2013, e26527.
47. Uherek, C., Tonn, T., Uherek, B., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100 (2002), 1265–1273.
48. Liu, H., Yang, B., Sun, T., et al. Specific growth inhibition of ErbB2expressing human breast cancer cells by genetically modified NK92 cells. Oncol Rep 33 (2015), 95–102.
49. Schonfeld, K., Sahm, C., Zhang, C., et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 23 (2015), 330–338.
50. Esser, R., Muller, T., Stefes, D., et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 16 (2012), 569–581.
51. Jiang, H., Zhang, W., Shang, P., et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 8 (2014), 297–310.
52. Sahm, C., Schonfeld, K., Wels, W.S., Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 61 (2012), 1451–1461.
53. Tassev, D.V., Cheng, M., Cheung, N.K., Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 19 (2012), 84–100.
54. Chu, J., Deng, Y., Benson, D.M., et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28 (2014), 917–927.
55. Lang, S., Vujanovic, N.L., Wollenberg, B., Whiteside, T.L., Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur J Immunol 28 (1998), 780–786.
56. Oelsner, S., Friede, M.E., Zhang, C., et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy 19 (2017), 235–249.
57. Chen, K.H., Wada, M., Pinz, K.G., et al. Preclinical targeting of aggressive T cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia, 2017 http://dx.doi.org/10.1038/leu.2017.8 [Epub ahead of print].
58. Massague, J., TGFbeta in cancer. Cell 134 (2008), 215–230.
59. Krneta, T., Gillgrass, A., Chew, M., Ashkar, A.A., The breast tumor microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol 13 (2016), 628–639.
60. Wang, Z., Guo, L., Song, Y., et al. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-betaR II and NKG2D. Cancer Immunol Immunother 66 (2017), 537–548.
61. Shimasaki, N., Campana, D., Natural killer cell reprogramming with chimeric immune receptors. Methods Mol Biol 969 (2013), 203–220.
62. Benlagha, K., Kyin, T., Beavis, A., Teyton, L., Bendelac, A., A thymic precursor to the NK T cell lineage. Science 296 (2002), 553–555.
63. Gapin, L., Matsuda, J.L., Surh, C.D., Kronenberg, M., NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2 (2001), 971–978.
64. Egawa, T., Eberl, G., Taniuchi, I., et al. Genetic evidence supporting selection of the Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity 22 (2005), 705–716.
65. Lantz, O., Bendelac, A., An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 180 (1994), 1097–1106.
66. Lee, P.T., Benlagha, K., Teyton, L., Bendelac, A., Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 195 (2002), 637–641.
67. Gumperz, J.E., Miyake, S., Yamamura, T., Brenner, M.B., Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195 (2002), 625–636.
68. Bendelac, A., CD1: presenting unusual antigens to unusual T lymphocytes. Science 269 (1995), 185–186.
69. Roark, J.H., Park, S.H., Jayawardena, J., Kavita, U., Shannon, M., Bendelac, A., CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J Immunol 160 (1998), 3121–3127.
70. Kawano, T., Cui, J., Koezuka, Y., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997), 1626–1629.
71. Hammond, K.J., Pelikan, S.B., Crowe, N.Y., et al. NKT cells are phenotypically and functionally diverse. Eur J Immunol 29 (1999), 3768–3781.
72. Uldrich, A.P., Crowe, N.Y., Kyparissoudis, K., et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175 (2005), 3092–3101.
73. Hayakawa, Y., Takeda, K., Yagita, H., Van Kaer, L., Saiki, I., Okumura, K., Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 166 (2001), 6012–6018.
74. Metelitsa, L.S., Wu, H.W., Wang, H., et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199 (2004), 1213–1221.
75. Tachibana, T., Onodera, H., Tsuruyama, T., et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11 (2005), 7322–7327.
76. Morris, E.S., MacDonald, K.P., Rowe, V., et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 115 (2005), 3093–3103.
77. Pillai, A.B., George, T.I., Dutt, S., Teo, P., Strober, S., Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 178 (2007), 6242–6251.
78. Casorati, G., de Lalla, C., Dellabona, P., Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation. Oncoimmunology 1 (2012), 355–357.
79. de Lalla, C., Rinaldi, A., Montagna, D., et al. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4- subset dynamics and correlates with remission state. J Immunol 186 (2011), 4490–4499.
80. Dellabona, P., Casorati, G., de Lalla, C., Montagna, D., Locatelli, F., On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clin Immunol 140 (2011), 152–159.
81. Song, L., Asgharzadeh, S., Salo, J., et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119 (2009), 1524–1536.
82. Hong, D.S., Angelo, L.S., Kurzrock, R., Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110 (2007), 1911–1928.
83. Pilones, K.A., Aryankalayil, J., Demaria, S., Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol, 2012, 2012, 720803.
84. Kawano, T., Nakayama, T., Kamada, N., et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59 (1999), 5102–5105.
85. Tahir, S.M., Cheng, O., Shaulov, A., et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167 (2001), 4046–4050.
86. Fujii, S., Shimizu, K., Klimek, V., Geller, M.D., Nimer, S.D., Dhodapkar, M.V., Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 122 (2003), 617–622.
87. Takahashi, T., Nieda, M., Koezuka, Y., et al. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 164 (2000), 4458–4464.
88. Rogers, P.R., Matsumoto, A., Naidenko, O., Kronenberg, M., Mikayama, T., Kato, S., Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000. J Immunol Methods 285 (2004), 197–214.
89. Motohashi, S., Ishikawa, A., Ishikawa, E., et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12 (2006), 6079–6086.
90. Metelitsa, L.S., Naidenko, O.V., Kant, A., et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167 (2001), 3114–3122.
91. Crowe, N.Y., Coquet, J.M., Berzins, S.P., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202 (2005), 1279–1288.
92. Bricard, G., Cesson, V., Devevre, E., et al. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 182 (2009), 5140–5151.
93. Osada, T., Morse, M.A., Lyerly, H.K., Clay, T.M., Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. Int Immunol 17 (2005), 1143–1155.
94. Terabe, M., Matsui, S., Noben-Trauth, N., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000), 515–520.
95. Park, J.M., Terabe, M., van den Broeke, L.T., Donaldson, D.D., Berzofsky, J.A., Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 114 (2005), 80–87.
96. Ostrand-Rosenberg, S., Clements, V.K., Terabe, M., Park, J.M., Berzofsky, J.A., Dissanayake, S.K., Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 169 (2002), 5796–5804.
97. Nieda, M., Okai, M., Tazbirkova, A., et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 (2004), 383–389.
98. Taniguchi, M., Seino, K., Nakayama, T., The NKT cell system: bridging innate and acquired immunity. Nat Immunol 4 (2003), 1164–1165.
99. Brossay, L., Chioda, M., Burdin, N., et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188 (1998), 1521–1528.
100. Heczey, A., Liu, D., Tian, G., et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124 (2014), 2824–2833.
101. Asgharzadeh, S., Salo, J.A., Ji, L., et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 30 (2012), 3525–3532.
102. Tian, G., Courtney, A.N., Jena, B., et al. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest 126 (2016), 2341–2355.
103. Graef, P., Buchholz, V.R., Stemberger, C., et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 41 (2014), 116–126.
104. Wang, X., Naranjo, A., Brown, C.E., et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 35 (2012), 689–701.
105. Sommermeyer, D., Hudecek, M., Kosasih, P.L., et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30 (2016), 492–500.
106. Raso, V., Griffin, T., Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res 41 (1981), 2073–2078.
107. Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov Today 20 (2015), 838–847.
108. Loffler, A., Kufer, P., Lutterbuse, R., et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95 (2000), 2098–2103.
109. Schlereth, B., Quadt, C., Dreier, T., et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 55 (2006), 503–514.
110. Topp, M.S., Gokbuget, N., Stein, A.S., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16 (2015), 57–66.
111. Topp, M.S., Gokbuget, N., Zugmaier, G., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32 (2014), 4134–4140.
112. Suryadevara, C.M., Gedeon, P.C., Sanchez-Perez, L., et al. Are BiTEs the “missing link” in cancer therapy?. Oncoimmunology, 4, 2015, e1008339.
113. Stone, J.D., Aggen, D.H., Schietinger, A., Schreiber, H., Kranz, D.M., A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology 1 (2012), 863–873.
114. Gleason, M.K., Verneris, M.R., Todhunter, D.A., et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 11 (2012), 2674–2684.
115. Vallera, D.A., Felices, M., McElmurry, R., et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res 22 (2016), 3440–3450.
116. Scheffold, C., Kornacker, M., Scheffold, Y.C., Contag, C.H., Negrin, R.S., Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Cancer Res 62 (2002), 5785–5791.
117. Chmielewski, M., Abken, H., TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15 (2015), 1145–1154.
118. Chmielewski, M., Kopecky, C., Hombach, A.A., Abken, H., IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71 (2011), 5697–5706.
119. Cheadle, E.J., Gornall, H., Baldan, V., Hanson, V., Hawkins, R.E., Gilham, D.E., CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 257 (2014), 91–106.
120. Pegram, H.J., Lee, J.C., Hayman, E.G., et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119 (2012), 4133–4141.